Joby's Milestone Gauntlet: Capital Raises Mask Progress

What happened

Joby Aviation trades near $7 after a 55% decline over the past year, with a new Seeking Alpha article calling the stock deeply undervalued due to progress toward eVTOL certification and near-term catalysts like eIPP services in Dallas-Fort Worth and Dubai. However, the master report maintains a WAIT rating, arguing that the next 6-9 months must deliver observable proof: FAA pilots starting for-credit TIA flights, Toyota closing its second $250 million tranche, and a date-certain Dubai launch. The article highlights a potential $750 million ATM capital raise tied to the $500 million Resonant Sciences acquisition, which would add a defense unit with $100 million-plus revenue but also increases dilution and debt. Master report notes $2.264 billion in liquidity and 75% completion of FAA Stage 4, but cash burn remains high and partnership headlines no longer move the stock. Overall, the setup is balanced rather than asymmetric: the balance sheet limits distress, but milestone conversion is required for upside.

Implication

The article's undervaluation claim rests on future milestones, not current fundamentals, and the master report's WAIT rating is appropriate because no hard catalyst has landed. The ATM raise and acquisition add potential revenue but also dilution and integration risk, which could pressure the stock further if milestones slip. The next 6-9 months are pivotal with checkpoints like FAA TIA testing, Toyota tranche, and Dubai launch, and investors should monitor these events closely. If at least one hard catalyst occurs, the stock could re-rate toward the $9-12 range, but if all three stall, the bear case of $6 becomes more likely. Position sizing should remain conservative, with the master report suggesting entry near $7 and trim above $10.50.

Thesis delta

The core thesis remains unchanged: Joby is a milestone-dependent story that needs observable proof of certification and manufacturing within 6-9 months. The new information on the Resonant Sciences acquisition and potential ATM raise adds a revenue stream and potential dilution, but it does not alter the near-term gating events. The master report's WAIT rating is reaffirmed, and the article's optimism is not yet supported by filed evidence.